nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefazolin—ABCC4—Sorafenib—kidney cancer	0.19	0.441	CbGbCtD
Cefazolin—ABCC4—Sunitinib—kidney cancer	0.154	0.358	CbGbCtD
Cefazolin—ALB—Erlotinib—kidney cancer	0.0866	0.201	CbGbCtD
Cefazolin—SLC22A8—nephron—kidney cancer	0.0164	0.136	CbGeAlD
Cefazolin—SLC22A8—urine—kidney cancer	0.0131	0.109	CbGeAlD
Cefazolin—SLC22A11—nephron tubule—kidney cancer	0.00626	0.052	CbGeAlD
Cefazolin—TPMT—nephron tubule—kidney cancer	0.00592	0.0492	CbGeAlD
Cefazolin—SLC22A6—nephron tubule—kidney cancer	0.0059	0.049	CbGeAlD
Cefazolin—SLC22A11—renal system—kidney cancer	0.00569	0.0473	CbGeAlD
Cefazolin—SLC22A11—kidney—kidney cancer	0.0055	0.0457	CbGeAlD
Cefazolin—TPMT—renal system—kidney cancer	0.00538	0.0447	CbGeAlD
Cefazolin—SLC22A11—cortex of kidney—kidney cancer	0.00536	0.0445	CbGeAlD
Cefazolin—TPMT—kidney—kidney cancer	0.0052	0.0433	CbGeAlD
Cefazolin—TPMT—cortex of kidney—kidney cancer	0.00507	0.0421	CbGeAlD
Cefazolin—SLC22A6—cortex of kidney—kidney cancer	0.00505	0.042	CbGeAlD
Cefazolin—TPMT—gonad—kidney cancer	0.00483	0.0401	CbGeAlD
Cefazolin—TPMT—cardiac atrium—kidney cancer	0.00482	0.0401	CbGeAlD
Cefazolin—ABCC4—nephron tubule—kidney cancer	0.00356	0.0296	CbGeAlD
Cefazolin—SLC22A8—nephron tubule—kidney cancer	0.00353	0.0294	CbGeAlD
Cefazolin—ABCC4—renal system—kidney cancer	0.00324	0.0269	CbGeAlD
Cefazolin—SLC22A8—renal system—kidney cancer	0.00321	0.0267	CbGeAlD
Cefazolin—ABCC4—kidney—kidney cancer	0.00313	0.026	CbGeAlD
Cefazolin—SLC22A8—kidney—kidney cancer	0.0031	0.0258	CbGeAlD
Cefazolin—ABCC4—cortex of kidney—kidney cancer	0.00305	0.0253	CbGeAlD
Cefazolin—SLC22A8—cortex of kidney—kidney cancer	0.00302	0.0251	CbGeAlD
Cefazolin—Haemorrhage—Paclitaxel—kidney cancer	0.000568	0.0013	CcSEcCtD
Cefazolin—Gastrointestinal pain—Erlotinib—kidney cancer	0.000568	0.0013	CcSEcCtD
Cefazolin—Vaginal infection—Doxorubicin—kidney cancer	0.000565	0.00129	CcSEcCtD
Cefazolin—Blood urea increased—Doxorubicin—kidney cancer	0.000565	0.00129	CcSEcCtD
Cefazolin—Aplastic anaemia—Doxorubicin—kidney cancer	0.000562	0.00128	CcSEcCtD
Cefazolin—Leukopenia—Vincristine—kidney cancer	0.000557	0.00127	CcSEcCtD
Cefazolin—Thrombocytopenia—Dactinomycin—kidney cancer	0.000557	0.00127	CcSEcCtD
Cefazolin—ABCC4—Fluoropyrimidine Activity—PPAT—kidney cancer	0.000556	0.0501	CbGpPWpGaD
Cefazolin—Pancytopenia—Capecitabine—kidney cancer	0.000553	0.00126	CcSEcCtD
Cefazolin—Dyspepsia—Sorafenib—kidney cancer	0.00055	0.00125	CcSEcCtD
Cefazolin—Body temperature increased—Erlotinib—kidney cancer	0.000549	0.00125	CcSEcCtD
Cefazolin—Abdominal pain—Erlotinib—kidney cancer	0.000549	0.00125	CcSEcCtD
Cefazolin—Anaemia—Gemcitabine—kidney cancer	0.000546	0.00125	CcSEcCtD
Cefazolin—Neutropenia—Capecitabine—kidney cancer	0.000545	0.00124	CcSEcCtD
Cefazolin—Decreased appetite—Sorafenib—kidney cancer	0.000543	0.00124	CcSEcCtD
Cefazolin—Anorexia—Dactinomycin—kidney cancer	0.000542	0.00124	CcSEcCtD
Cefazolin—Nausea—Pazopanib—kidney cancer	0.000541	0.00123	CcSEcCtD
Cefazolin—Mouth ulceration—Doxorubicin—kidney cancer	0.000541	0.00123	CcSEcCtD
Cefazolin—Convulsion—Vincristine—kidney cancer	0.00054	0.00123	CcSEcCtD
Cefazolin—Fatigue—Sorafenib—kidney cancer	0.000538	0.00123	CcSEcCtD
Cefazolin—Erythema multiforme—Paclitaxel—kidney cancer	0.000537	0.00123	CcSEcCtD
Cefazolin—Pain—Sorafenib—kidney cancer	0.000534	0.00122	CcSEcCtD
Cefazolin—Hypersensitivity—Vinblastine—kidney cancer	0.000532	0.00121	CcSEcCtD
Cefazolin—TPMT—Biological oxidations—ACY1—kidney cancer	0.000532	0.048	CbGpPWpGaD
Cefazolin—Hypersensitivity—Everolimus—kidney cancer	0.00053	0.00121	CcSEcCtD
Cefazolin—Dyspepsia—Sunitinib—kidney cancer	0.000529	0.00121	CcSEcCtD
Cefazolin—Leukopenia—Gemcitabine—kidney cancer	0.000529	0.00121	CcSEcCtD
Cefazolin—Hypertonia—Doxorubicin—kidney cancer	0.000525	0.0012	CcSEcCtD
Cefazolin—Decreased appetite—Sunitinib—kidney cancer	0.000522	0.00119	CcSEcCtD
Cefazolin—Asthenia—Vinblastine—kidney cancer	0.000518	0.00118	CcSEcCtD
Cefazolin—Fatigue—Sunitinib—kidney cancer	0.000518	0.00118	CcSEcCtD
Cefazolin—Asthenia—Everolimus—kidney cancer	0.000516	0.00118	CcSEcCtD
Cefazolin—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000515	0.00118	CcSEcCtD
Cefazolin—Pain—Sunitinib—kidney cancer	0.000514	0.00117	CcSEcCtD
Cefazolin—Gastrointestinal pain—Sorafenib—kidney cancer	0.000511	0.00117	CcSEcCtD
Cefazolin—Renal failure—Capecitabine—kidney cancer	0.000511	0.00117	CcSEcCtD
Cefazolin—Pruritus—Everolimus—kidney cancer	0.000509	0.00116	CcSEcCtD
Cefazolin—Anaphylactic shock—Vincristine—kidney cancer	0.000508	0.00116	CcSEcCtD
Cefazolin—Stomatitis—Capecitabine—kidney cancer	0.000506	0.00116	CcSEcCtD
Cefazolin—Phlebitis—Doxorubicin—kidney cancer	0.000504	0.00115	CcSEcCtD
Cefazolin—Asthenia—Erlotinib—kidney cancer	0.000498	0.00114	CcSEcCtD
Cefazolin—Thrombocytopenia—Vincristine—kidney cancer	0.000498	0.00114	CcSEcCtD
Cefazolin—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000497	0.00113	CcSEcCtD
Cefazolin—Urticaria—Sorafenib—kidney cancer	0.000496	0.00113	CcSEcCtD
Cefazolin—Decreased appetite—Dactinomycin—kidney cancer	0.000495	0.00113	CcSEcCtD
Cefazolin—Diarrhoea—Vinblastine—kidney cancer	0.000494	0.00113	CcSEcCtD
Cefazolin—Body temperature increased—Sorafenib—kidney cancer	0.000494	0.00113	CcSEcCtD
Cefazolin—Abdominal pain—Sorafenib—kidney cancer	0.000494	0.00113	CcSEcCtD
Cefazolin—Diarrhoea—Everolimus—kidney cancer	0.000492	0.00112	CcSEcCtD
Cefazolin—Gastrointestinal pain—Sunitinib—kidney cancer	0.000491	0.00112	CcSEcCtD
Cefazolin—Pruritus—Erlotinib—kidney cancer	0.000491	0.00112	CcSEcCtD
Cefazolin—Fatigue—Dactinomycin—kidney cancer	0.00049	0.00112	CcSEcCtD
Cefazolin—Flatulence—Paclitaxel—kidney cancer	0.000487	0.00111	CcSEcCtD
Cefazolin—Pain—Dactinomycin—kidney cancer	0.000486	0.00111	CcSEcCtD
Cefazolin—Agranulocytosis—Capecitabine—kidney cancer	0.000485	0.00111	CcSEcCtD
Cefazolin—Anorexia—Vincristine—kidney cancer	0.000484	0.00111	CcSEcCtD
Cefazolin—Anaphylactic shock—Gemcitabine—kidney cancer	0.000482	0.0011	CcSEcCtD
Cefazolin—Dizziness—Vinblastine—kidney cancer	0.000478	0.00109	CcSEcCtD
Cefazolin—Dizziness—Everolimus—kidney cancer	0.000476	0.00109	CcSEcCtD
Cefazolin—Body temperature increased—Sunitinib—kidney cancer	0.000475	0.00108	CcSEcCtD
Cefazolin—Abdominal pain—Sunitinib—kidney cancer	0.000475	0.00108	CcSEcCtD
Cefazolin—Diarrhoea—Erlotinib—kidney cancer	0.000475	0.00108	CcSEcCtD
Cefazolin—Hypotension—Vincristine—kidney cancer	0.000475	0.00108	CcSEcCtD
Cefazolin—Thrombocytopenia—Gemcitabine—kidney cancer	0.000472	0.00108	CcSEcCtD
Cefazolin—Feeling abnormal—Dactinomycin—kidney cancer	0.000469	0.00107	CcSEcCtD
Cefazolin—Haemoglobin—Capecitabine—kidney cancer	0.000469	0.00107	CcSEcCtD
Cefazolin—Haemorrhage—Capecitabine—kidney cancer	0.000466	0.00106	CcSEcCtD
Cefazolin—Hepatitis—Capecitabine—kidney cancer	0.000466	0.00106	CcSEcCtD
Cefazolin—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000465	0.00106	CcSEcCtD
Cefazolin—Hypersensitivity—Sorafenib—kidney cancer	0.00046	0.00105	CcSEcCtD
Cefazolin—Anorexia—Gemcitabine—kidney cancer	0.00046	0.00105	CcSEcCtD
Cefazolin—Vomiting—Vinblastine—kidney cancer	0.000459	0.00105	CcSEcCtD
Cefazolin—Dizziness—Erlotinib—kidney cancer	0.000459	0.00105	CcSEcCtD
Cefazolin—Vomiting—Everolimus—kidney cancer	0.000457	0.00104	CcSEcCtD
Cefazolin—Anaemia—Paclitaxel—kidney cancer	0.000457	0.00104	CcSEcCtD
Cefazolin—Agitation—Paclitaxel—kidney cancer	0.000455	0.00104	CcSEcCtD
Cefazolin—Rash—Everolimus—kidney cancer	0.000454	0.00104	CcSEcCtD
Cefazolin—Dermatitis—Everolimus—kidney cancer	0.000453	0.00103	CcSEcCtD
Cefazolin—Headache—Vinblastine—kidney cancer	0.000452	0.00103	CcSEcCtD
Cefazolin—Headache—Everolimus—kidney cancer	0.000451	0.00103	CcSEcCtD
Cefazolin—Hypotension—Gemcitabine—kidney cancer	0.000451	0.00103	CcSEcCtD
Cefazolin—Abdominal pain—Dactinomycin—kidney cancer	0.00045	0.00103	CcSEcCtD
Cefazolin—Body temperature increased—Dactinomycin—kidney cancer	0.00045	0.00103	CcSEcCtD
Cefazolin—Asthenia—Sorafenib—kidney cancer	0.000448	0.00102	CcSEcCtD
Cefazolin—Syncope—Paclitaxel—kidney cancer	0.000444	0.00101	CcSEcCtD
Cefazolin—Leukopenia—Paclitaxel—kidney cancer	0.000443	0.00101	CcSEcCtD
Cefazolin—Hypersensitivity—Sunitinib—kidney cancer	0.000443	0.00101	CcSEcCtD
Cefazolin—Decreased appetite—Vincristine—kidney cancer	0.000442	0.00101	CcSEcCtD
Cefazolin—Pruritus—Sorafenib—kidney cancer	0.000442	0.00101	CcSEcCtD
Cefazolin—Vomiting—Erlotinib—kidney cancer	0.000441	0.00101	CcSEcCtD
Cefazolin—Erythema multiforme—Capecitabine—kidney cancer	0.000441	0.00101	CcSEcCtD
Cefazolin—Fatigue—Vincristine—kidney cancer	0.000438	0.001	CcSEcCtD
Cefazolin—Rash—Erlotinib—kidney cancer	0.000438	0.000999	CcSEcCtD
Cefazolin—Dermatitis—Erlotinib—kidney cancer	0.000437	0.000998	CcSEcCtD
Cefazolin—Headache—Erlotinib—kidney cancer	0.000435	0.000992	CcSEcCtD
Cefazolin—Loss of consciousness—Paclitaxel—kidney cancer	0.000435	0.000992	CcSEcCtD
Cefazolin—Pain—Vincristine—kidney cancer	0.000435	0.000992	CcSEcCtD
Cefazolin—Asthenia—Sunitinib—kidney cancer	0.000431	0.000984	CcSEcCtD
Cefazolin—Nausea—Vinblastine—kidney cancer	0.000429	0.000979	CcSEcCtD
Cefazolin—Somnolence—Gemcitabine—kidney cancer	0.000429	0.000978	CcSEcCtD
Cefazolin—Convulsion—Paclitaxel—kidney cancer	0.000429	0.000978	CcSEcCtD
Cefazolin—Nausea—Everolimus—kidney cancer	0.000427	0.000975	CcSEcCtD
Cefazolin—Diarrhoea—Sorafenib—kidney cancer	0.000427	0.000975	CcSEcCtD
Cefazolin—Pruritus—Sunitinib—kidney cancer	0.000425	0.00097	CcSEcCtD
Cefazolin—Decreased appetite—Gemcitabine—kidney cancer	0.000419	0.000956	CcSEcCtD
Cefazolin—Hypersensitivity—Dactinomycin—kidney cancer	0.000419	0.000956	CcSEcCtD
Cefazolin—Fatigue—Gemcitabine—kidney cancer	0.000416	0.000949	CcSEcCtD
Cefazolin—Gastrointestinal pain—Vincristine—kidney cancer	0.000416	0.000948	CcSEcCtD
Cefazolin—Dizziness—Sorafenib—kidney cancer	0.000413	0.000942	CcSEcCtD
Cefazolin—Pain—Gemcitabine—kidney cancer	0.000412	0.000941	CcSEcCtD
Cefazolin—Nausea—Erlotinib—kidney cancer	0.000412	0.000941	CcSEcCtD
Cefazolin—Diarrhoea—Sunitinib—kidney cancer	0.000411	0.000938	CcSEcCtD
Cefazolin—Asthenia—Dactinomycin—kidney cancer	0.000408	0.000931	CcSEcCtD
Cefazolin—Confusional state—Paclitaxel—kidney cancer	0.000407	0.000929	CcSEcCtD
Cefazolin—Blood creatinine increased—Doxorubicin—kidney cancer	0.000407	0.000929	CcSEcCtD
Cefazolin—Anaphylactic shock—Paclitaxel—kidney cancer	0.000404	0.000921	CcSEcCtD
Cefazolin—Abdominal pain—Vincristine—kidney cancer	0.000402	0.000917	CcSEcCtD
Cefazolin—Body temperature increased—Vincristine—kidney cancer	0.000402	0.000917	CcSEcCtD
Cefazolin—Flatulence—Capecitabine—kidney cancer	0.0004	0.000913	CcSEcCtD
Cefazolin—Dizziness—Sunitinib—kidney cancer	0.000397	0.000907	CcSEcCtD
Cefazolin—Feeling abnormal—Gemcitabine—kidney cancer	0.000397	0.000907	CcSEcCtD
Cefazolin—Shock—Paclitaxel—kidney cancer	0.000397	0.000906	CcSEcCtD
Cefazolin—Vomiting—Sorafenib—kidney cancer	0.000397	0.000906	CcSEcCtD
Cefazolin—Abdominal pain upper—Doxorubicin—kidney cancer	0.000397	0.000905	CcSEcCtD
Cefazolin—Thrombocytopenia—Paclitaxel—kidney cancer	0.000395	0.000902	CcSEcCtD
Cefazolin—Rash—Sorafenib—kidney cancer	0.000394	0.000898	CcSEcCtD
Cefazolin—Dermatitis—Sorafenib—kidney cancer	0.000393	0.000898	CcSEcCtD
Cefazolin—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000391	0.000893	CcSEcCtD
Cefazolin—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000391	0.000893	CcSEcCtD
Cefazolin—Headache—Sorafenib—kidney cancer	0.000391	0.000893	CcSEcCtD
Cefazolin—Diarrhoea—Dactinomycin—kidney cancer	0.000389	0.000888	CcSEcCtD
Cefazolin—Anorexia—Paclitaxel—kidney cancer	0.000385	0.000878	CcSEcCtD
Cefazolin—Vomiting—Sunitinib—kidney cancer	0.000382	0.000872	CcSEcCtD
Cefazolin—Body temperature increased—Gemcitabine—kidney cancer	0.000381	0.00087	CcSEcCtD
Cefazolin—Rash—Sunitinib—kidney cancer	0.000379	0.000865	CcSEcCtD
Cefazolin—Dermatitis—Sunitinib—kidney cancer	0.000379	0.000864	CcSEcCtD
Cefazolin—Hypotension—Paclitaxel—kidney cancer	0.000377	0.000861	CcSEcCtD
Cefazolin—Headache—Sunitinib—kidney cancer	0.000376	0.000859	CcSEcCtD
Cefazolin—Anaemia—Capecitabine—kidney cancer	0.000375	0.000856	CcSEcCtD
Cefazolin—Hypersensitivity—Vincristine—kidney cancer	0.000374	0.000854	CcSEcCtD
Cefazolin—Eosinophilia—Doxorubicin—kidney cancer	0.000372	0.000848	CcSEcCtD
Cefazolin—Nausea—Sorafenib—kidney cancer	0.000371	0.000846	CcSEcCtD
Cefazolin—Asthenia—Vincristine—kidney cancer	0.000365	0.000832	CcSEcCtD
Cefazolin—Syncope—Capecitabine—kidney cancer	0.000364	0.000831	CcSEcCtD
Cefazolin—Leukopenia—Capecitabine—kidney cancer	0.000363	0.000829	CcSEcCtD
Cefazolin—Vomiting—Dactinomycin—kidney cancer	0.000362	0.000825	CcSEcCtD
Cefazolin—Somnolence—Paclitaxel—kidney cancer	0.000359	0.000819	CcSEcCtD
Cefazolin—Rash—Dactinomycin—kidney cancer	0.000359	0.000818	CcSEcCtD
Cefazolin—Nausea—Sunitinib—kidney cancer	0.000357	0.000814	CcSEcCtD
Cefazolin—Loss of consciousness—Capecitabine—kidney cancer	0.000357	0.000814	CcSEcCtD
Cefazolin—Pancytopenia—Doxorubicin—kidney cancer	0.000357	0.000814	CcSEcCtD
Cefazolin—Dyspepsia—Paclitaxel—kidney cancer	0.000355	0.000811	CcSEcCtD
Cefazolin—Neutropenia—Doxorubicin—kidney cancer	0.000351	0.000801	CcSEcCtD
Cefazolin—Decreased appetite—Paclitaxel—kidney cancer	0.000351	0.000801	CcSEcCtD
Cefazolin—Fatigue—Paclitaxel—kidney cancer	0.000348	0.000794	CcSEcCtD
Cefazolin—Diarrhoea—Vincristine—kidney cancer	0.000348	0.000794	CcSEcCtD
Cefazolin—Asthenia—Gemcitabine—kidney cancer	0.000346	0.000789	CcSEcCtD
Cefazolin—Pain—Paclitaxel—kidney cancer	0.000345	0.000788	CcSEcCtD
Cefazolin—Pruritus—Gemcitabine—kidney cancer	0.000341	0.000778	CcSEcCtD
Cefazolin—Nausea—Dactinomycin—kidney cancer	0.000338	0.000771	CcSEcCtD
Cefazolin—Dizziness—Vincristine—kidney cancer	0.000336	0.000767	CcSEcCtD
Cefazolin—Confusional state—Capecitabine—kidney cancer	0.000334	0.000762	CcSEcCtD
Cefazolin—Feeling abnormal—Paclitaxel—kidney cancer	0.000333	0.000759	CcSEcCtD
Cefazolin—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000332	0.000757	CcSEcCtD
Cefazolin—Gastrointestinal pain—Paclitaxel—kidney cancer	0.00033	0.000753	CcSEcCtD
Cefazolin—Diarrhoea—Gemcitabine—kidney cancer	0.00033	0.000753	CcSEcCtD
Cefazolin—Renal failure—Doxorubicin—kidney cancer	0.000329	0.000751	CcSEcCtD
Cefazolin—Stomatitis—Doxorubicin—kidney cancer	0.000326	0.000745	CcSEcCtD
Cefazolin—Shock—Capecitabine—kidney cancer	0.000326	0.000744	CcSEcCtD
Cefazolin—Thrombocytopenia—Capecitabine—kidney cancer	0.000324	0.00074	CcSEcCtD
Cefazolin—Vomiting—Vincristine—kidney cancer	0.000323	0.000737	CcSEcCtD
Cefazolin—Urticaria—Paclitaxel—kidney cancer	0.000321	0.000732	CcSEcCtD
Cefazolin—Rash—Vincristine—kidney cancer	0.00032	0.000731	CcSEcCtD
Cefazolin—Dermatitis—Vincristine—kidney cancer	0.00032	0.000731	CcSEcCtD
Cefazolin—Body temperature increased—Paclitaxel—kidney cancer	0.000319	0.000728	CcSEcCtD
Cefazolin—Abdominal pain—Paclitaxel—kidney cancer	0.000319	0.000728	CcSEcCtD
Cefazolin—Headache—Vincristine—kidney cancer	0.000318	0.000727	CcSEcCtD
Cefazolin—Anorexia—Capecitabine—kidney cancer	0.000316	0.000721	CcSEcCtD
Cefazolin—Agranulocytosis—Doxorubicin—kidney cancer	0.000312	0.000713	CcSEcCtD
Cefazolin—Hypotension—Capecitabine—kidney cancer	0.00031	0.000706	CcSEcCtD
Cefazolin—Vomiting—Gemcitabine—kidney cancer	0.000307	0.0007	CcSEcCtD
Cefazolin—Rash—Gemcitabine—kidney cancer	0.000304	0.000694	CcSEcCtD
Cefazolin—Dermatitis—Gemcitabine—kidney cancer	0.000304	0.000693	CcSEcCtD
Cefazolin—Haemoglobin—Doxorubicin—kidney cancer	0.000302	0.000689	CcSEcCtD
Cefazolin—Headache—Gemcitabine—kidney cancer	0.000302	0.000689	CcSEcCtD
Cefazolin—Nausea—Vincristine—kidney cancer	0.000302	0.000689	CcSEcCtD
Cefazolin—Haemorrhage—Doxorubicin—kidney cancer	0.000301	0.000686	CcSEcCtD
Cefazolin—Hepatitis—Doxorubicin—kidney cancer	0.000301	0.000686	CcSEcCtD
Cefazolin—Hypersensitivity—Paclitaxel—kidney cancer	0.000297	0.000679	CcSEcCtD
Cefazolin—TPMT—Phase II conjugation—GSTT1—kidney cancer	0.000293	0.0264	CbGpPWpGaD
Cefazolin—Dyspepsia—Capecitabine—kidney cancer	0.000292	0.000665	CcSEcCtD
Cefazolin—TPMT—Biological oxidations—ALDH1A1—kidney cancer	0.000291	0.0263	CbGpPWpGaD
Cefazolin—Asthenia—Paclitaxel—kidney cancer	0.00029	0.000661	CcSEcCtD
Cefazolin—ABCC4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000288	0.026	CbGpPWpGaD
Cefazolin—Decreased appetite—Capecitabine—kidney cancer	0.000288	0.000657	CcSEcCtD
Cefazolin—Nausea—Gemcitabine—kidney cancer	0.000286	0.000654	CcSEcCtD
Cefazolin—Fatigue—Capecitabine—kidney cancer	0.000286	0.000652	CcSEcCtD
Cefazolin—Pruritus—Paclitaxel—kidney cancer	0.000286	0.000652	CcSEcCtD
Cefazolin—Erythema multiforme—Doxorubicin—kidney cancer	0.000284	0.000648	CcSEcCtD
Cefazolin—Pain—Capecitabine—kidney cancer	0.000283	0.000646	CcSEcCtD
Cefazolin—Diarrhoea—Paclitaxel—kidney cancer	0.000276	0.00063	CcSEcCtD
Cefazolin—Feeling abnormal—Capecitabine—kidney cancer	0.000273	0.000623	CcSEcCtD
Cefazolin—Gastrointestinal pain—Capecitabine—kidney cancer	0.000271	0.000618	CcSEcCtD
Cefazolin—Dizziness—Paclitaxel—kidney cancer	0.000267	0.000609	CcSEcCtD
Cefazolin—Urticaria—Capecitabine—kidney cancer	0.000263	0.000601	CcSEcCtD
Cefazolin—Abdominal pain—Capecitabine—kidney cancer	0.000262	0.000598	CcSEcCtD
Cefazolin—Body temperature increased—Capecitabine—kidney cancer	0.000262	0.000598	CcSEcCtD
Cefazolin—Flatulence—Doxorubicin—kidney cancer	0.000258	0.000588	CcSEcCtD
Cefazolin—Vomiting—Paclitaxel—kidney cancer	0.000257	0.000586	CcSEcCtD
Cefazolin—Rash—Paclitaxel—kidney cancer	0.000255	0.000581	CcSEcCtD
Cefazolin—Dermatitis—Paclitaxel—kidney cancer	0.000254	0.00058	CcSEcCtD
Cefazolin—Headache—Paclitaxel—kidney cancer	0.000253	0.000577	CcSEcCtD
Cefazolin—Hypersensitivity—Capecitabine—kidney cancer	0.000244	0.000557	CcSEcCtD
Cefazolin—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000243	0.0219	CbGpPWpGaD
Cefazolin—Anaemia—Doxorubicin—kidney cancer	0.000242	0.000552	CcSEcCtD
Cefazolin—Agitation—Doxorubicin—kidney cancer	0.00024	0.000549	CcSEcCtD
Cefazolin—Nausea—Paclitaxel—kidney cancer	0.00024	0.000547	CcSEcCtD
Cefazolin—Asthenia—Capecitabine—kidney cancer	0.000238	0.000542	CcSEcCtD
Cefazolin—Syncope—Doxorubicin—kidney cancer	0.000235	0.000535	CcSEcCtD
Cefazolin—Pruritus—Capecitabine—kidney cancer	0.000234	0.000535	CcSEcCtD
Cefazolin—Leukopenia—Doxorubicin—kidney cancer	0.000234	0.000534	CcSEcCtD
Cefazolin—Loss of consciousness—Doxorubicin—kidney cancer	0.00023	0.000525	CcSEcCtD
Cefazolin—Convulsion—Doxorubicin—kidney cancer	0.000227	0.000517	CcSEcCtD
Cefazolin—Diarrhoea—Capecitabine—kidney cancer	0.000227	0.000517	CcSEcCtD
Cefazolin—Dizziness—Capecitabine—kidney cancer	0.000219	0.0005	CcSEcCtD
Cefazolin—ABCC4—Ectoderm Differentiation—CDH6—kidney cancer	0.000217	0.0196	CbGpPWpGaD
Cefazolin—Confusional state—Doxorubicin—kidney cancer	0.000215	0.000491	CcSEcCtD
Cefazolin—Anaphylactic shock—Doxorubicin—kidney cancer	0.000214	0.000487	CcSEcCtD
Cefazolin—Vomiting—Capecitabine—kidney cancer	0.000211	0.000481	CcSEcCtD
Cefazolin—Shock—Doxorubicin—kidney cancer	0.00021	0.000479	CcSEcCtD
Cefazolin—Thrombocytopenia—Doxorubicin—kidney cancer	0.000209	0.000477	CcSEcCtD
Cefazolin—Rash—Capecitabine—kidney cancer	0.000209	0.000477	CcSEcCtD
Cefazolin—Dermatitis—Capecitabine—kidney cancer	0.000209	0.000476	CcSEcCtD
Cefazolin—ALB—HDL-mediated lipid transport—SCARB1—kidney cancer	0.000208	0.0187	CbGpPWpGaD
Cefazolin—Headache—Capecitabine—kidney cancer	0.000208	0.000474	CcSEcCtD
Cefazolin—Anorexia—Doxorubicin—kidney cancer	0.000204	0.000464	CcSEcCtD
Cefazolin—TPMT—Phase II conjugation—GSTP1—kidney cancer	0.000203	0.0183	CbGpPWpGaD
Cefazolin—Hypotension—Doxorubicin—kidney cancer	0.0002	0.000455	CcSEcCtD
Cefazolin—Nausea—Capecitabine—kidney cancer	0.000197	0.000449	CcSEcCtD
Cefazolin—Somnolence—Doxorubicin—kidney cancer	0.00019	0.000433	CcSEcCtD
Cefazolin—Dyspepsia—Doxorubicin—kidney cancer	0.000188	0.000429	CcSEcCtD
Cefazolin—TPMT—Phase II conjugation—GSTM1—kidney cancer	0.000186	0.0168	CbGpPWpGaD
Cefazolin—Decreased appetite—Doxorubicin—kidney cancer	0.000186	0.000424	CcSEcCtD
Cefazolin—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000185	0.0167	CbGpPWpGaD
Cefazolin—Fatigue—Doxorubicin—kidney cancer	0.000184	0.00042	CcSEcCtD
Cefazolin—Pain—Doxorubicin—kidney cancer	0.000183	0.000417	CcSEcCtD
Cefazolin—Feeling abnormal—Doxorubicin—kidney cancer	0.000176	0.000402	CcSEcCtD
Cefazolin—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000175	0.000398	CcSEcCtD
Cefazolin—TPMT—Biological oxidations—GSTT1—kidney cancer	0.000171	0.0154	CbGpPWpGaD
Cefazolin—Urticaria—Doxorubicin—kidney cancer	0.00017	0.000387	CcSEcCtD
Cefazolin—Body temperature increased—Doxorubicin—kidney cancer	0.000169	0.000385	CcSEcCtD
Cefazolin—Abdominal pain—Doxorubicin—kidney cancer	0.000169	0.000385	CcSEcCtD
Cefazolin—ABCC4—Ectoderm Differentiation—NF2—kidney cancer	0.000165	0.0148	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—PTGS1—kidney cancer	0.00016	0.0145	CbGpPWpGaD
Cefazolin—ABCC4—ABC-family proteins mediated transport—ABCB1—kidney cancer	0.000158	0.0143	CbGpPWpGaD
Cefazolin—ALB—FOXA2 and FOXA3 transcription factor networks—HNF1A—kidney cancer	0.000158	0.0142	CbGpPWpGaD
Cefazolin—Hypersensitivity—Doxorubicin—kidney cancer	0.000157	0.000359	CcSEcCtD
Cefazolin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000155	0.014	CbGpPWpGaD
Cefazolin—Asthenia—Doxorubicin—kidney cancer	0.000153	0.00035	CcSEcCtD
Cefazolin—Pruritus—Doxorubicin—kidney cancer	0.000151	0.000345	CcSEcCtD
Cefazolin—Diarrhoea—Doxorubicin—kidney cancer	0.000146	0.000333	CcSEcCtD
Cefazolin—Dizziness—Doxorubicin—kidney cancer	0.000141	0.000322	CcSEcCtD
Cefazolin—Vomiting—Doxorubicin—kidney cancer	0.000136	0.00031	CcSEcCtD
Cefazolin—Rash—Doxorubicin—kidney cancer	0.000135	0.000307	CcSEcCtD
Cefazolin—Dermatitis—Doxorubicin—kidney cancer	0.000135	0.000307	CcSEcCtD
Cefazolin—Headache—Doxorubicin—kidney cancer	0.000134	0.000305	CcSEcCtD
Cefazolin—ABCC4—NRF2 pathway—SLC5A3—kidney cancer	0.000128	0.0116	CbGpPWpGaD
Cefazolin—Nausea—Doxorubicin—kidney cancer	0.000127	0.000289	CcSEcCtD
Cefazolin—ALB—Lipoprotein metabolism—SCARB1—kidney cancer	0.000119	0.0108	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—GSTP1—kidney cancer	0.000119	0.0107	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—GSTP1—kidney cancer	0.000117	0.0106	CbGpPWpGaD
Cefazolin—ABCC4—NRF2 pathway—KEAP1—kidney cancer	0.000112	0.0101	CbGpPWpGaD
Cefazolin—SLC22A11—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000111	0.00997	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—GSTM1—kidney cancer	0.000109	0.00984	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—GSTM1—kidney cancer	0.000108	0.0097	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—CYP1A1—kidney cancer	0.000103	0.00932	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—CYP1A1—kidney cancer	0.000102	0.0092	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—RYR1—kidney cancer	9.78e-05	0.00882	CbGpPWpGaD
Cefazolin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SCARB1—kidney cancer	9.3e-05	0.00839	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ACY1—kidney cancer	9.09e-05	0.0082	CbGpPWpGaD
Cefazolin—ABCC4—Platelet degranulation—IGF2—kidney cancer	8.58e-05	0.00774	CbGpPWpGaD
Cefazolin—SLC22A8—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	8.43e-05	0.0076	CbGpPWpGaD
Cefazolin—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF2—kidney cancer	8.17e-05	0.00737	CbGpPWpGaD
Cefazolin—ALB—Lipid and lipoprotein metabolism—SCARB1—kidney cancer	7.93e-05	0.00716	CbGpPWpGaD
Cefazolin—ABCC4—Ectoderm Differentiation—PAX6—kidney cancer	7.82e-05	0.00706	CbGpPWpGaD
Cefazolin—ALB—Vitamin B12 Metabolism—SCARB1—kidney cancer	7.81e-05	0.00704	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PDHB—kidney cancer	7.73e-05	0.00697	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—POMC—kidney cancer	7.71e-05	0.00695	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—RYR1—kidney cancer	7.46e-05	0.00673	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—CCBL1—kidney cancer	7.27e-05	0.00656	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—RYR1—kidney cancer	7.15e-05	0.00645	CbGpPWpGaD
Cefazolin—SLC22A6—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	7.03e-05	0.00635	CbGpPWpGaD
Cefazolin—ABCC4—NRF2 pathway—SLC5A5—kidney cancer	6.76e-05	0.0061	CbGpPWpGaD
Cefazolin—ABCC4—NRF2 pathway—SLC2A1—kidney cancer	6.53e-05	0.00589	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—SCARB1—kidney cancer	6.35e-05	0.00573	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GLIPR1—kidney cancer	6.3e-05	0.00569	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PPAT—kidney cancer	6.3e-05	0.00569	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—L1CAM—kidney cancer	6.26e-05	0.00565	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—RYR1—kidney cancer	6.22e-05	0.00561	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—ITPR2—kidney cancer	6.19e-05	0.00558	CbGpPWpGaD
Cefazolin—ABCC4—NRF2 pathway—EGR1—kidney cancer	6.06e-05	0.00547	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—APRT—kidney cancer	5.86e-05	0.00529	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—FH—kidney cancer	5.86e-05	0.00529	CbGpPWpGaD
Cefazolin—SLC22A11—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	5.83e-05	0.00526	CbGpPWpGaD
Cefazolin—SLC22A11—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	5.63e-05	0.00508	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—ATP7B—kidney cancer	5.62e-05	0.00507	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—ANXA2—kidney cancer	5.62e-05	0.00507	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—SLC5A3—kidney cancer	5.62e-05	0.00507	CbGpPWpGaD
Cefazolin—ABCC4—Fluoropyrimidine Activity—TP53—kidney cancer	5.52e-05	0.00498	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GPC3—kidney cancer	5.51e-05	0.00497	CbGpPWpGaD
Cefazolin—ABCC4—NRF2 pathway—GSTP1—kidney cancer	5.45e-05	0.00491	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—CA2—kidney cancer	5.36e-05	0.00483	CbGpPWpGaD
Cefazolin—ALB—Vitamin B12 Metabolism—SOD2—kidney cancer	5.27e-05	0.00476	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ALAD—kidney cancer	5.22e-05	0.00471	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ST3GAL2—kidney cancer	5.1e-05	0.0046	CbGpPWpGaD
Cefazolin—ALB—Selenium Micronutrient Network—SCARB1—kidney cancer	5.05e-05	0.00455	CbGpPWpGaD
Cefazolin—ABCC4—NRF2 pathway—GSTM1—kidney cancer	5.01e-05	0.00452	CbGpPWpGaD
Cefazolin—ALB—Selenium Micronutrient Network—PTGS1—kidney cancer	5e-05	0.00451	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ALDH1A1—kidney cancer	4.98e-05	0.00449	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—SLC5A3—kidney cancer	4.78e-05	0.00431	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PGK1—kidney cancer	4.78e-05	0.00431	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—ANXA2—kidney cancer	4.74e-05	0.00428	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—LDHB—kidney cancer	4.68e-05	0.00423	CbGpPWpGaD
Cefazolin—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	4.45e-05	0.00401	CbGpPWpGaD
Cefazolin—SLC22A8—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	4.29e-05	0.00387	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—SOD2—kidney cancer	4.29e-05	0.00387	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—ANXA2—kidney cancer	4.28e-05	0.00386	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—SLC5A3—kidney cancer	4.28e-05	0.00386	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—ATP7B—kidney cancer	4.28e-05	0.00386	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—ATP7B—kidney cancer	4.11e-05	0.0037	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—ANXA2—kidney cancer	4.11e-05	0.0037	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—SLC5A3—kidney cancer	4.11e-05	0.0037	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—CA9—kidney cancer	4.06e-05	0.00366	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—KCNMA1—kidney cancer	3.93e-05	0.00355	CbGpPWpGaD
Cefazolin—ALB—Platelet degranulation—IGF2—kidney cancer	3.88e-05	0.0035	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—IGF2—kidney cancer	3.8e-05	0.00343	CbGpPWpGaD
Cefazolin—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	3.71e-05	0.00335	CbGpPWpGaD
Cefazolin—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—kidney cancer	3.7e-05	0.00334	CbGpPWpGaD
Cefazolin—ALB—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	3.66e-05	0.0033	CbGpPWpGaD
Cefazolin—ABCC4—Platelet degranulation—VEGFA—kidney cancer	3.6e-05	0.00324	CbGpPWpGaD
Cefazolin—SLC22A6—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	3.58e-05	0.00323	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—SLC5A3—kidney cancer	3.57e-05	0.00322	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—ATP7B—kidney cancer	3.57e-05	0.00322	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—ANXA2—kidney cancer	3.57e-05	0.00322	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—CRABP1—kidney cancer	3.45e-05	0.00312	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—GRB7—kidney cancer	3.43e-05	0.00309	CbGpPWpGaD
Cefazolin—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—kidney cancer	3.43e-05	0.00309	CbGpPWpGaD
Cefazolin—ALB—Selenium Micronutrient Network—SOD2—kidney cancer	3.41e-05	0.00308	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—RYR1—kidney cancer	3.24e-05	0.00292	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ITPR2—kidney cancer	3.21e-05	0.0029	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—ITPR2—kidney cancer	3.19e-05	0.00288	CbGpPWpGaD
Cefazolin—ALB—Vitamin B12 Metabolism—RELA—kidney cancer	3.05e-05	0.00275	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.96e-05	0.00267	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GSTT1—kidney cancer	2.93e-05	0.00264	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ACHE—kidney cancer	2.93e-05	0.00264	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.86e-05	0.00258	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—L1CAM—kidney cancer	2.83e-05	0.00255	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—ITPR2—kidney cancer	2.8e-05	0.00252	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—SCARB1—kidney cancer	2.77e-05	0.0025	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PTGS1—kidney cancer	2.74e-05	0.00247	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PSMD7—kidney cancer	2.69e-05	0.00243	CbGpPWpGaD
Cefazolin—ABCC4—Ectoderm Differentiation—CTNNB1—kidney cancer	2.64e-05	0.00238	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	2.58e-05	0.00233	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—BCHE—kidney cancer	2.55e-05	0.0023	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—SLC5A5—kidney cancer	2.52e-05	0.00227	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—RELA—kidney cancer	2.48e-05	0.00224	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—SLC2A1—kidney cancer	2.43e-05	0.00219	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—IFNA1—kidney cancer	2.34e-05	0.00211	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.26e-05	0.00204	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.26e-05	0.00204	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—IL2—kidney cancer	2.23e-05	0.00201	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.18e-05	0.00197	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—IFNA2—kidney cancer	2.18e-05	0.00196	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.17e-05	0.00195	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—ANXA2—kidney cancer	2.15e-05	0.00194	CbGpPWpGaD
Cefazolin—ABCC4—Ectoderm Differentiation—MYC—kidney cancer	2.14e-05	0.00193	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—RAF1—kidney cancer	2.09e-05	0.00189	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.09e-05	0.00189	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GSTP1—kidney cancer	2.03e-05	0.00183	CbGpPWpGaD
Cefazolin—ALB—Selenium Micronutrient Network—RELA—kidney cancer	1.97e-05	0.00178	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—IGF2—kidney cancer	1.96e-05	0.00177	CbGpPWpGaD
Cefazolin—ALB—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	1.93e-05	0.00174	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ABCB1—kidney cancer	1.92e-05	0.00173	CbGpPWpGaD
Cefazolin—ALB—Selenium Micronutrient Network—PTGS2—kidney cancer	1.91e-05	0.00173	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.89e-05	0.0017	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—IL2—kidney cancer	1.88e-05	0.00169	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GSTM1—kidney cancer	1.86e-05	0.00168	CbGpPWpGaD
Cefazolin—ALB—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	1.86e-05	0.00168	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—SLC5A3—kidney cancer	1.86e-05	0.00168	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—ATP7B—kidney cancer	1.86e-05	0.00168	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—ANXA2—kidney cancer	1.86e-05	0.00168	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.82e-05	0.00164	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—KCNMA1—kidney cancer	1.78e-05	0.0016	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—CYP1A1—kidney cancer	1.77e-05	0.00159	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.72e-05	0.00155	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—IGF2—kidney cancer	1.72e-05	0.00155	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ACY1—kidney cancer	1.66e-05	0.00149	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.65e-05	0.00149	CbGpPWpGaD
Cefazolin—ALB—Platelet degranulation—VEGFA—kidney cancer	1.63e-05	0.00147	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	1.6e-05	0.00144	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—GRB7—kidney cancer	1.55e-05	0.0014	CbGpPWpGaD
Cefazolin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—kidney cancer	1.55e-05	0.0014	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	1.51e-05	0.00136	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—ITPR2—kidney cancer	1.44e-05	0.0013	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.44e-05	0.0013	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	1.44e-05	0.0013	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—TP53—kidney cancer	1.43e-05	0.00129	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	1.41e-05	0.00127	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PDHB—kidney cancer	1.41e-05	0.00127	CbGpPWpGaD
Cefazolin—ALB—Metabolism—CCBL1—kidney cancer	1.32e-05	0.00119	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—POMC—kidney cancer	1.32e-05	0.00119	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—RAF1—kidney cancer	1.28e-05	0.00115	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	1.25e-05	0.00112	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	1.2e-05	0.00108	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GLIPR1—kidney cancer	1.15e-05	0.00104	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PPAT—kidney cancer	1.15e-05	0.00104	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	1.13e-05	0.00102	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	1.12e-05	0.00101	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—RAF1—kidney cancer	1.08e-05	0.000973	CbGpPWpGaD
Cefazolin—ALB—Metabolism—FH—kidney cancer	1.07e-05	0.000963	CbGpPWpGaD
Cefazolin—ALB—Metabolism—APRT—kidney cancer	1.07e-05	0.000963	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—IFNA1—kidney cancer	1.06e-05	0.000955	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PTGS2—kidney cancer	1.05e-05	0.000948	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.04e-05	0.000941	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GPC3—kidney cancer	1e-05	0.000905	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—IFNA2—kidney cancer	9.86e-06	0.000889	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—SLC5A5—kidney cancer	9.8e-06	0.000884	CbGpPWpGaD
Cefazolin—ALB—Metabolism—CA2—kidney cancer	9.76e-06	0.000881	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—RAF1—kidney cancer	9.74e-06	0.000879	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—IL2—kidney cancer	9.68e-06	0.000873	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ALAD—kidney cancer	9.52e-06	0.000858	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—RAF1—kidney cancer	9.47e-06	0.000855	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—SLC2A1—kidney cancer	9.47e-06	0.000854	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—RAF1—kidney cancer	9.34e-06	0.000843	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ST3GAL2—kidney cancer	9.29e-06	0.000838	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PTEN—kidney cancer	9.17e-06	0.000827	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ALDH1A1—kidney cancer	9.08e-06	0.000819	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—IGF2—kidney cancer	8.87e-06	0.0008	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PGK1—kidney cancer	8.7e-06	0.000785	CbGpPWpGaD
Cefazolin—ALB—Metabolism—SLC5A3—kidney cancer	8.7e-06	0.000785	CbGpPWpGaD
Cefazolin—ALB—Metabolism—LDHB—kidney cancer	8.53e-06	0.00077	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—IL2—kidney cancer	8.5e-06	0.000766	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—VEGFA—kidney cancer	8.22e-06	0.000742	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—RAF1—kidney cancer	8.13e-06	0.000734	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—MAPK3—kidney cancer	7.78e-06	0.000702	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.47e-06	0.000674	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—MAPK1—kidney cancer	7.4e-06	0.000668	CbGpPWpGaD
Cefazolin—ALB—Metabolism—CA9—kidney cancer	7.4e-06	0.000667	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.23e-06	0.000652	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	7.22e-06	0.000651	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—KRAS—kidney cancer	6.99e-06	0.000631	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	6.83e-06	0.000616	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	6.5e-06	0.000586	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PIK3CA—kidney cancer	6.47e-06	0.000583	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—PIK3CA—kidney cancer	6.42e-06	0.000579	CbGpPWpGaD
Cefazolin—ALB—Metabolism—CRABP1—kidney cancer	6.29e-06	0.000568	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—TP53—kidney cancer	6.21e-06	0.000561	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ITPR2—kidney cancer	5.85e-06	0.000528	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	5.64e-06	0.000509	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.39e-06	0.000486	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ACHE—kidney cancer	5.33e-06	0.000481	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTT1—kidney cancer	5.33e-06	0.000481	CbGpPWpGaD
Cefazolin—ALB—Metabolism—SCARB1—kidney cancer	5.05e-06	0.000455	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PTGS1—kidney cancer	5e-06	0.000451	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PSMD7—kidney cancer	4.9e-06	0.000442	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—RAF1—kidney cancer	4.88e-06	0.000441	CbGpPWpGaD
Cefazolin—ALB—Metabolism—BCHE—kidney cancer	4.65e-06	0.000419	CbGpPWpGaD
Cefazolin—ALB—Metabolism—SLC5A5—kidney cancer	4.59e-06	0.000414	CbGpPWpGaD
Cefazolin—ALB—Metabolism—SLC2A1—kidney cancer	4.43e-06	0.0004	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—IL2—kidney cancer	4.38e-06	0.000395	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.3e-06	0.000388	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	4.23e-06	0.000381	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.75e-06	0.000338	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—VEGFA—kidney cancer	3.72e-06	0.000336	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTP1—kidney cancer	3.7e-06	0.000334	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—MAPK3—kidney cancer	3.52e-06	0.000318	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ABCB1—kidney cancer	3.5e-06	0.000316	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTM1—kidney cancer	3.4e-06	0.000306	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—MAPK1—kidney cancer	3.35e-06	0.000302	CbGpPWpGaD
Cefazolin—ALB—Metabolism—CYP1A1—kidney cancer	3.22e-06	0.000291	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—KRAS—kidney cancer	3.16e-06	0.000285	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—PIK3CA—kidney cancer	2.91e-06	0.000262	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—TP53—kidney cancer	2.81e-06	0.000254	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.65e-06	0.000239	CbGpPWpGaD
Cefazolin—ALB—Metabolism—POMC—kidney cancer	2.4e-06	0.000217	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PTGS2—kidney cancer	1.92e-06	0.000173	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PTEN—kidney cancer	1.67e-06	0.000151	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PIK3CA—kidney cancer	1.18e-06	0.000106	CbGpPWpGaD
